Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Open accessThe DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.
Abstract
Since the late 1990s, therapy for metastatic colorectal cancer (mCRC) has changed considerably, and the combination of doublet or triplet chemotherapy and a targeted agent are now routinely used. The targeting of angiogenesis, the development of new blood vessels, represents a key element in the overall treatment strategy. Since the approval in 2004 of the first anti-angiogenetic drug, multiple agents have been approved and others are currently under investigation. We present an overview of the recent literature on approved systemic treatment of mCRC, with a focus on anti-angiogenic drugs, and current treatment approaches, and elaborate on the future role of angiogenesis in colorectal cancer as seen from a clinical perspective. The treatment of mCRC, in general, has changed from “one strategy fits all” to a more personalized approach. This is, however, not entirely the case for anti-angiogenetic treatments, partly due to a lack of validated biomarkers. The anti-angiogenetic standard treatment at the present primarily includes monoclonal antibodies. The therapeutic field of angiogenesis, however, has received increased interest after the introduction of newer combinations. These approaches will likely change the current treatment strategy, once again, to the overall benefit of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, few clinical trials suggested an improved response rate, while others showed increased toxicity without significant survival benefit.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Different types of anti-angiogenic agents are used to block the VEGF-VEGFR signaling axis, including mAbs (bevacizumab, ramucirumab), soluble decoy receptors (ziv-aflibercept), and small molecule multi-kinase inhibitors (regorafenib) [35].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Approximately half of the patients will be diagnosed with metastatic CRC (mCRC), at either the time of diagnosis (synchronous) or due to later recurrence (metachronous) [1].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“In combination with IFL, a bolus regimen consisting of irinotecan and 5-fluorouracil (5FU), OS was extended by almost five months to 20 months [7].”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“In 1971, Judah Folkman described tumors’ dependence on newly formed blood vessels waking the interest in angiogenesis as a process for pharmaceutical targeting [73,74].”
BackgroundPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 3×
“Reversing th se processes through anti-angiogenetic treatment are summarized in the normalizatio th ory pr sented by Rak h Jain [72] and later proven clinically.”
BackgroundMethodInfluentialMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“Once connected to adjacent sprouts the entire process reverses in order to stabilize and mature the newly formed blood vessel [77].”
BackgroundWhat Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531 · cited 1×
“In 1971, Judah Folkman described tumors’ dependence on newly formed blood vessels waking the interest in angiogenesis as a process for pharmaceutical targeting [73,74].”
BackgroundAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276 · cited 1×
“Basically, the term vasculogenesis describes the process of the initial endothelial differentiation of angioblasts during embryogenesis [18], whereas angiogenesis refers to the formation of new blood vessels from existing endothelial cells [19].”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 5×
“Inhibition of tumor-associated angiogenesis have been utilized for the treatment of patients with mCRC for more than 15 years [2,3].”
BackgroundMethodInfluentialSelf-citationSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Different types of anti-angiogenic agents are used to block the VEGF-VEGFR signaling axis, including mAbs (bevacizumab, ramucirumab), soluble decoy receptors (ziv-aflibercept), and small molecule multi-kinase inhibitors (regorafenib) [35].”
Revisiting the therapeutic potential of tocotrienol
Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022) · BioFactors · doi:10.1002/biof.1873 · Cited by 97
Nanotechnology for colorectal cancer detection and treatment
Gogoi, P., Kaur, G., & Singh, N. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i46.6497 · Cited by 82
Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
Ajmeera, D., & Ajumeera, R. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.12.013 · Cited by 68
Dokhanchi, M., Pakravan, K., Zareian, S., Hussen, B. M., Farid, M., Razmara, E., Mohammadi, M. M., Cho, W. C. S., & Babashah, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119937 · Cited by 63
Metadata
- Authors
- Hansen, T. F., Qvortrup, C., & Pfeiffer, P.
- Affiliations
- University of Southern Denmark (DK)
- Rigshospitalet (DK)
- Corresponding author
- Hansen, Torben Frøstrup
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-03-01
- Volume
- 13
- Issue
- 5
- Pages
- 1031
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7957514
- OpenAlex
- W3135049650
- Cited by
- 43
- References
- 99
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 9 · 2021: 2
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- angiogenesis inhibitors, metastatic colorectal cancer, anti-angiogenic therapy, monoclonal antibodies, targeted therapy, combination chemotherapy, personalized treatment, biomarkers, systemic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. https://app.cochat.ai/papers/10.3390/cancers13051031
- The paper
- Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021). Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers. https://doi.org/10.3390/cancers13051031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.